Aspyre Lung Variant Calling in NSCLC Samples

This research article investigates the efficacy of Aspyre Lung, a targeted genomic profiling assay, in enhancing variant calling for non-small cell lung cancer (NSCLC) samples that fail next-generation sequencing (NGS) quality control. The study profiles 198 NSCLC patient tissue samples, divided into two cohorts: Cohort A, which includes samples that failed NGS quality checks, and Cohort B, which comprises samples that successfully underwent NGS testing. The results indicate that Aspyre Lung successfully processed 96% of samples from Cohort A, yielding genomic results in 47% of these previously uninformative samples. In Cohort B, all samples passed Aspyre Lung quality control, demonstrating a 97% concordance with NGS results. The findings suggest that Aspyre Lung is a viable rapid screening tool that can rescue samples that would otherwise be discarded due to NGS failures, thus facilitating timely access to targeted therapies for patients with NSCLC. The article outlines the methodology, results, and implications for clinical practice in precision oncology.